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Summary:  
 Background: The use of haploidentical stem cell transplantation (HSCT) 
 has recently arisen as an effective treatment for refractory hematological 
 malignancies, and several approaches have been shown to offer similar 
 outcomes to HLA-matched allogeneic HSCT with the benefit of a larger 
 and more accessible donor pool, particularly in smaller countries and 
 ethnic minorities. High-dose post-transplant cyclophosphamide (PTCy) is 
 a simple and well-studied approach being newly utilized at UHC Zagreb.  
 Objective: We evaluated several key outcomes of patients receiving 
 haploidentical HSCT at UHC Zagreb in order to determine whether they 
 were acceptable in comparison to other centers performing    
haploidentical HSCT as well as studies of HLA-matched HSCT.  
 Methods: In a retrospective study, ten patients with various refractory 
 myelogenous and lymphoid malignancies underwent PTCy haploidentical 
 HSCT at UHC Zagreb from 2012-2015. Both myeloablative and RIC 
 conditioning regimens were employed. Data was collected towards the 
 primary endpoints of engraftment, relapse and GVHD rates.  
 Results: Median times to neutrophil and thrombocyte recovery were 12 
 and 21 days post-transplant, respectively. Relapse rates were 50%, with 
 a mean relapse time of 5.6 months. Rejection rate was 10%. NRM was 
 20% with a median time of 15.3 months. Acute and chronic GVHD rates 
 were 10% and 30% respectively, with a mean diagnosis time of 11.2 
 months for chronic GVHD.  
 Conclusion: HLA-haploidentical HSCT at UHC Zagreb using PTCy is 
 associated with acceptable rates of engraftment, relapse, and GVHD. 
 Keywords: stem cell transplantation, haploidentical, graft-versus-host, 
           post-transplantation cyclophosphamide
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1. Introduction 
 The use of hematopoietic stem cell transplantation has been a therapy 
used alone or in conjunction with chemotherapy and radiation to treat a variety 
of hematologic malignant and nonmalignant diseases for over 50 years (1), with 
varying but consistently improving results, so much so that these transplants 
(previously referred to as bone marrow transplants) are now an expected 
secondary modality of treatment in patients who have had recurrences after 
standard chemotherapy regimens (2).  
 Allogeneic HSCT is the only possible curative therapy for a number of 
hematological malignancies, as well as a number of non-malignant diseases 
such as severe combined immunodeficiencies and aplastic anemia. However, 
only 30% of patients have an available family HLA-identical donor (3). The 
probability of having a fully-matched sibling is 1-(0.75), where N= number of 
siblings (4). For other patients we have the possibility of finding an unrelated 
HLA-matched donor, but still for a considerable portion of patients we are 
unable to identify an MUD, particularly for patients who belong to a certain 
ethnic group (5). In the case of Croatia, biobanking of bone marrow donors and 
cord blood donors are recorded through their respective organizations, but are 
sporadically utilized and limited in scope (6). Haploidentical transplantation is a 
method that was underused previously due to an increased incidence of graft 
rejection compared to HLA-matched donors, as well as increased incidence of 
severe GVHD (7). In recent times, due to the increasing need for non-traditional 
donor pools in HSCT, researchers have revisited the possibility of using 
haploidentical donors, and three major approaches have been developed.  
 T-cell depletion (TCD) is an important component of ensuring low rates 
of acute and chronic GVHD, and this can be achieved ex vivo via 
immunomagnetic selection of CD34+ before donation, or in vivo with infusion of 
antithymocyte globulin (ATG) in the donor (8). Addition of a megadose infusion 
of CD34+ into the recipient will result in a niche competition, wherein stem cells 
have a preferential advantage over any remaining donor T-cells. 
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Early studies showed development of conditioning-resistant anti-donor T-
cells. Therefore, disease-free survival (DFS) is low, and NRM using the TCD 
approach is high due to the patient’s increased susceptibility to infections, 
especially due to reactivation of viruses such as cytomegalovirus and Epstein-
Barr virus (9). 
 The GIAC strategy, first applied in Peking University and Beijing Air 
Force University in China, uses in vivo modulation of allografts without T-cell 
eradication. GIAC is an acronym for a protocol that consists of GCSF-
stimulation of the donor pre-transplant, intensified immunosuppression, 
Antithymocyte globulin infusion for the recipient during conditioning, and a 
combined PBSC and bone marrow grafting. T-cells in the stimulated grafts were 
less proliferative and were more likely to differentiate to Th2 cells than Th1 
(recognized as a greater stimulator of a GVHD response), thought to be caused 
by an increase in IL-10 secretion and a downregulation of CD86 expression on 
antigen-presenting cells (4). This technique comes with the caveat of being 
complex, and faces significant rates of GVHD and an increased risk of infection 
due to the depression of Th1 differentiation in the donor grafts (10). 
 At UHC Zagreb, we decided to proceed with haploidentical 
transplantation using post-transplantation cyclophosphamide application (the 
“Baltimore” protocol) as our institutional protocol. Since 1963, murine studies 
demonstrated beneficial host tolerance to skin allografts using post-
transplantation cyclophosphamide (4). Mechanisms of cyclophosphamide are 
direct elimination of host and donor alloreactive T-cells that are proliferative, 
while sparing quiescent alloreactive T-cells such as those that are virus-specific 
(11). PTCy also affects intrathymic clonal deletion of alloreactive T-cells, though 
this effect is less pronounced in adults. Essential to the favorable profile of 
PTCy is the sparing of host CD4+ regulatory T-cells, which promote tolerance to 
donor grafts and help prevent GVHD (12). This is due to high secretion by T-reg 
cells of aldehyde dehydrogenase, an enzyme that degrades cyclophosphamide. 
Low doses of cyclophosphamide and fludarabine are given pre-transplantation 
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as part of reduced-intensity conditioning, and TBI of 200cGy is administered on 
the day before transplantation. PTCy is given on days 3 and 4, and MMF on day 
5 until an average of 35 days post-transplantation (13). Tacrolimus is also 
started on day 5 and terminates variably on presence and presentation of 
GVHD signs, usually 180 days (Figure 1).  
 
 
 
   
 
 
 
 
Figure 1. Visual representation of Baltimore RIC and post-transplantation 
cyclophosphamide regimen. Taken from (13) with permission under Creative 
Commons license.  
  
 A 2002 Johns Hopkins phase I study using a single dose of PTCy on day 
3 with T-cell replete haploBMT patients showed an 80% engraftment rate, 60% 
acute GVHD grade II-IV, and 60% survival after a median follow-up period of 
284 days. A subsequent phase II study added a second PTCy dose on day 4 
and prolonged tacrolimus treatment resulted in improved engraftment rate, an 
acute GVHD rate of 34%, and a reduction of extensive chronic GVHD from 25% 
to 5%. Nonrelapse mortality (NRM) due to infection was limited to two patients 
who died of fungal infection, and none of the patients had detectable CMV 
reactivation or EBV-linked lymphoproliferative disease (4). Remarkably, there 
was no observable effect on the degree of HLA disparity in reference to acute 
GVHD or progression-free survival. A large number of studies using this 
protocol points to similar outcomes using PTCy haploBMT with alloBMT using 
HLA-matched sibling or MUD (14).  
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Risks of high dosages of cyclophosphamide can include hemorrhagic 
cystitis, a condition also attributable to reactivation of the BK virus and one 
which is treatable. A comparison of haplo-HSCT to both matched related donors 
and MUD by Bashey found equivalent outcomes between all groups when using 
this approach, with an improvement over the matched groups in disease-free 
survival (15). Overall, the relative simplicity, familiarity, and favorable outcomes 
of PTCy make it a desirable option for treatment in centers where matched 
sibling donors are unavailable and matched unrelated donors are harder to find 
due to demographic considerations.  
 
2. Hypothesis 
 The preliminary trials with patients receiving HLA-haploidentical HSCT at 
UHC Zagreb with a post-transplant cyclophosphamide regimen is feasible and 
results in acceptable rates of graft rejection as well as GVHD incidence. 
 
3. Objectives 
 This retrospective study will focus on the primary objective of 
investigating the rejection rates for haploidentical HSCT and acute and chronic 
GVHD incidence in patients transplanted at UHC Zagreb. In addition, we will 
investigate secondary aims of patient outcomes over our observational period. 
These will include survival without disease progression, overall survival, NRM, 
and rates of hematopoietic recovery.  
 
4. Methods 
4.1 Study population 
 Ten patients with various hematological malignancies were transplanted 
with haploidentical HSCT using the post-transplant cyclophosphamide regimen 
at UHC Zagreb. Transplantations were performed from 24 May 2012 until 15 
September 2015, and data was collected on these patients through February 
2016.  
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This is a retrospective study of the outcomes previously listed in the Objectives 
section. More detailed information can be found below in Table 1. 
 
Table 1. Patient characteristics receiving HSCT at UHC Zagreb. 
  
Pt. # DOB Gender Primary 
Dg 
Date of Dg Previous lines of 
therapy 
Donor 
relation 
Donor 
type 
Conditio-
ning 
1 8.9.1964 M AML 
arising 
from 
JAK2+ 
myelofib
rosis 
1.9.2011 DCEx1 (9.2011), HAM 
(10.2011), 1+5 
(11.2011), 6-thioguanine 
(12.2011) 
son Combin
ed bone 
marrow/ 
PBSC 
Baltimore 
2 7.5.1974 M T-ALL 1.5.2012 GRAALL (5.2012), 
HyperCVADx7 (11.2012) 
mother Bone 
marrow 
Baltimore 
3 5.5.1957 M AML 25.11.2013 DCEx1 (10.2013), DIA 
consolidation (10.2013) 
daughter Bone 
marrow 
Baltimore 
4 15.6.1973 M CML 
(Philadel
phia) 
2.9.2013 Hydroxyurea (10.2013), 
nilotinib/dasatinib 
(5.2014), fludarabine & 
cyclophosphamide 
(11.2014) 
mother Bone 
marrow 
Baltimore 
5 27.7.1969 F AML 3.2014 Hydroxyurea & DCEx1 
(4.2014), DIA (6.2014), 
MRC (8.2014), 1+5 
(10.2014)
daughter Bone 
marrow 
Baltimore 
6 21.1.1952 M AML 16.7.2014 3+7 (7.2014), NOVIAx1 
consolidation, 2+5 & 
mitoxantrone
daughter Bone 
marrow 
Baltimore 
7 28.7.1952 F AML 
arising 
from 
MDS 
8.2014 
(MDS) 
Azacitidine x7 (9.2014), 
DCE x1 (5.2015), DIA 
(7.2015) 
mother Bone 
marrow 
Baltimore 
8 26.2.1988 M HL 2012 
(primary), 
13.4.2014 
(relapse) 
ABVD x4 & rituximab 
(2012), HDIM 
x2/miniBEAM, 
autotransplant (9.2013), 
BEAM/eBEACOPP/Br+D
HAP x2/brentuximab 
(8.2014)
father Bone 
marrow 
Baltimore 
9 24.12.1985 F AML 
arising 
from 
MDS 
4.2015 
(MDS) 
BISHOP/DIA x1 (6.2015) sister PBSC BuCy 
10 15.11.1981 F AML 1.11.2013 ICE/DIA 
x1/HAM/autologous 
transplant (11.2013), 
FLAG-IDA/HAM (4.2015)
brother Bone 
marrow 
BuCy 
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4.2 Ethics statement 
 This study has been approved by the Institutional Review Board at UHC 
Zagreb and the University of Zagreb Medical School. Retrospective data is used 
and all patient identifying information is removed in compliance with protection 
of patient privacy.  
 
4.3 Transplant protocols 
 Transplantation was carried out at the Department of Hematology at 
UHC Zagreb. Eight patients received unmanipulated bone marrow transplants, 
one patient received PBSC only, and one patient received a combination of 
bone marrow and PBSC.  
 Conditioning for the recipient followed the RIC Baltimore protocol 
(fludarabine 30mg/m² IV on days -6 to -2 pre-transplant, cyclophosphamide 
14.5mg/kv IV on days -3 and -2, and TBI of 200cGy on day -1) in eight patients. 
Two patients received a standard myeloablative conditioning regimen of 
busulfan 3.2mg/kg IV on days -7 to -4 pre-transplant, and cyclophosphamide 
60mg/kg IV on days -3 and -2 (16). 
 
4.4 Post-transplant cyclophosphamide and immunosuppression 
 All patients were administered a post-transplant cyclophosphamide 
regimen and immunosuppressive therapy as shown in Figure 1. MMF was 
discontinued on day 35 post-transplant and tacrolimus was administered for an 
mean of 180 days or by the discretion of the attending physician on follow-up. 
Mesna is used as a treatment in the event of development of hemorrhagic 
cystitis.  
 
4.5 Tracking of patient data 
All patient data for this study was recorded and updated on BIS, the electronic 
medical recording system used in medical centers across Croatia.  
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5. Results 
Baseline characteristic 
As seen in Table 1, our patients were 60% male and 40% female, 
ranging in age from 28 to 64 with a mean age of 44.5 years. 70% of our patients 
were indicated for transplant on the diagnosis of refractory acute myelogenous 
leukemia, and two of those patients had refractory AML that arose from 
myelodysplastic syndrome, which increased the likelihood of relapse due to 
resistance to previous lines of chemotherapy. Previous lines of therapy shown 
in Table 1 were appropriate to the treatment of the patients’ primary diagnoses 
but were ultimately unsuccessful in preventing relapse. 
 
5.1 Hematopoietic markers of engraftment 
 Of our ten patients, complete data on recovery of thrombocytes and 
absolute neutrophil count (ANC) was available for seven. Median thrombocyte 
recovery time was 12 days and neutrophil recovery at 21 days. Our patients 
showed a significant positive correlation between the amount of infused donor 
CD34+ hematopoietic stem cells from the donor and recovery times for 
neutrophils and thrombocytes.  Furthermore, there was an increased incidence 
of GVHD in those patients with impaired recovery of thrombocytes from 20,000 
to 50,000 as seen in the spike at 51 days. The data in Figure 2 shows identical 
patterns when comparing engraftment markers to the quantity of CD3+ 
(cytotoxic T-lymphocyte) cells infused.  
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  Figure 2. Recovery of hematopoietic markers in transplanted 
patients. 
 
 
 
5.2 Rates of Relapse and Rejection 
 50% of the patients in our study encountered relapse of their primary 
disease over the course of our study, with a mean relapse time of 5.6 months 
post-transplant. Relapse was determined by cytology at UHC Zagreb. Patients 
who relapsed were majority male, had positive cytogenetic markers for poor 
prognosis, and all were over 40 years old.  
 One patient’s cytology suggested transplant rejection 17 months post-
transplantation. He subsequently received a PBSC infusion from his mother but 
post-transplant data was not available to include this into the study. 
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Figure 3. Disease-free survival. 
 
5.3 Nonrelapse mortality 
 Two patients (20%) died during the period of observation, with a median 
time of 460 days or 15.3 months. Both patients were male over the age of 40, 
which indicate a higher risk for complications post-transplant according to the 
Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI).(Sorror) Cause 
of death in both patients was multisystem organ failure. 
 
5.4 Development of GVHD 
 Determination of acute and chronic GVHD was made by clinical 
observation on follow-up and confirmed by biopsy in the Pathology department 
of UHC Zagreb. Acute GVHD less than 100 days post-transplant was observed 
in only one patient, who developed a maculopapular rash.  
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 Three patients (30%) developed chronic GVHD, with a mean time to 
diagnosis of 11.2 months or 336 days. These patients were all over the age of 
40. Presentations included ocular irritation and gastrointestinal erosions and 
bleeding. Two of these patients also had sclerodermatous hyperpigmented 
patches which were confirmed as grade II-IV on the NIH organ grading table. 
There was no observable association between delayed recovery of 
thrombocytes and development of GVHD in these patients.  
 
 
Figure 4. Development of chronic GVHD. 
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5.5 Development of infection 
 All donors and recipients were screened for antibodies against CMV 
before transplant; all participants showed positive immunoglobulin G and 
negative active infection. One patient showed reactivation of CMV post-
transplant as evidenced by presence of CMV DNA. 
 Two patients (20%) had complications related to the development of 
bacterial infections. One patient was released on day 43 post-transplant after 
treatment for vancomycin-resistant enterococcus, S. epidermidis dermatitis, and 
colistin-sensitive P. aeruginosa. The other patient, who underwent a 
splenectomy previous to transplantation, was treated for two episodes of sepsis 
and intestinal candidiasis.  
 
6. Discussion 
6.1 Hematopoietic markers of engraftment 
 These markers are important as they are a signifier of effective 
engraftment of donor cells. An ANC above 500 cells/μL is the clinical threshold 
for neutropenia and marks a clinical milestone in the recipient’s ability to ward 
off bacterial infection. Thrombocyte counts below 20,000/μL is associated with 
risk of severe bleeding and thrombocyte counts below 50,000/μL that do not 
improve after further platelet transfusions are a marker of secondary failure of 
platelet recovery (SFPR), and are associated with higher rates of acute and 
chronic GVHD in those patients. (10). 
  Our rates of ANC and thrombocyte recovery are comparable to a study 
that showed median recovery times of 15 days for neutrophils and 24 days for 
thrombocytes (4), but in our case the numbers have been flipped. While the 
association between a larger donor stem cell infusion and reduced time to 
recovery remains, our small sample size led to an aberration that make a 
generalization difficult.  
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 Several studies have confirmed the link between amount of CD34+ cell 
infusion quantity and positive outcomes (17). Stimulation of the donor with 
granulocyte colony stimulating factor will markedly increase the amount of 
hematopoietic stem cells and a threshold of 2.5*10^6/kg cells infused will 
ensure sustained engraftment in most cases of HLA-matched transplants. 
Recovery of thrombocytes to 20,000/μl by day 14 and neutrophil count to 5
should take place by day 12 in these patients. (12). Our results compared 
similarly with HLA-matched patients in this regard.  
00/μl 
  The presence of a high number of donor CD3+ T-lymphocytes in the 
graft is also associated with increased engraftment, lower infection rates, and a 
graft-vs-leukemia effect in the setting of the recipient’s dysfunctional immune 
system. Donor CD4+ cells aid in the prevention of bacterial infection and CD8+ 
cells induce a graft-versus-leukemia effect that will continue to foster the 
conditions for stem cell homing and engraftment (10).  
 
6.2 Rates of Relapse and Rejection 
  Rates of relapse in several studies (4, 17) show an incidence in one-
year relapse of 50%; this was consistent with our findings, although our patients 
had an earlier mean occurrence of relapse compared with other studies. There 
was an increased likelihood of relapse in relation to myelogenous malignancies 
than with lymphoid malignancies. Relapse was the major cause of treatment 
failure in our sample group.  
 The effect of GVL in patients treated with a RIC regimen has been shown 
to lead to lower NRM and treatment-related mortality but a higher relapse rate, 
leading to similar rates of overall survival for patients compared to 
myeloablative regimens (18, 16). The two patients with BuCy myelo
conditioning did not experience relapse in our observation period.  
 
ablative 
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6.3 Nonrelapse mortality 
 Non-relapse mortality, as shown in other studies, has a tendency to level 
out between 1 and 2 years post-transplant, at a rate of 15% (4) for 
haploidentical HSCT, compared with 20% in our group, who died at 405 and 
516 days post-transplant, respectively.  
These patients were both over the age of 40 (putting them at higher risk 
of complications according to HCT-CI) and showed previous complications with 
primary therapies including treatment interruptions and a relapse of 
myelodysplastic syndrome pre-transplant.  
  
6 v.4 De elopment of GVHD 
 Occurence of GVHD is common to any tissue transplant from an 
immunocompetent donor into an immunocompromised recipient, and the clinical 
significance of this phenomenon in the setting of HSCT must be balanced with 
the effect of donor tissue on GVL, and against the possibility of graft failure (21). 
This is correlated with the degree of HLA disparity, resulting in greater 
alloreactivity in a bidirectional manner (17,19).  
 Our rate of acute GVHD (10%) was lower than that found in other studies 
(Luznik Odonnell)(Bashey) of 25-34%. This result should not be suggestive of 
any conclusion other than our small sample size, regardless of the high skill 
level of physicians and staff at UHC Zagreb.  
 Surveys of patients with active chronic GVHD show a marked decrease 
in physical activity and social functioning, as well as an increase in pain and 
emotional and cognitive functioning (20). Determination and grading of chronic 
GVHD was made using NIH criteria, but also involve an interdisciplinary team of 
specialists to determine emergence and development of symptoms that affect 
multiple organs. Rising rates of chronic GVHD can be attributed to the 
availability of allogeneic HSCT to older and more high-risk patients, and rates 
for chronic cGVHD in all allogeneic patients approach 50% (22).  
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Studies for haploidentical HSCT show a moderate-severe chronic GVHD 
rate of 13-20% after 1 year (2,13). Our cGVHD incidence of 30% is higher than 
rates found in other haploidentical studies; however, the small sample size may 
have been a factor in this result. The continuation of haploidentical HSCT using 
PTCy at UHC Zagreb will increase the data pool.  
 
6.5 Development of infection 
 Persistent viruses such as EBV and CMV are normally controlled through 
CD8+ cytotoxic T-lymphocyte response, and incidence approaches 50% in 
some studies, but that the CD8+ count during reconstitution may be less 
important than recovery of CD4+ T-cells and NK cells as immune modulators 
(11). Furthermore, there is evidence of an association between development of 
CMV viremia and a reduced incidence of relapse in haploHSCT patients. On the 
reverse side of this, GVHD rates were higher in CMV-reactivated patients, likely 
due to a mechanism of greater differentiation toward and activity of cytotoxic T-
lymphocytes (23). Our one patient (10%) with CMV reactivation shows an 
overall lower incidence than other haploHSCT studies. The use of 
immunosuppression in recipients with tacrolimus, MMF, and corticosteroid 
therapy has the dual result of preventing GVHD in early stages and resulting in 
a higher chance for infection.  
 
7. Conclusions 
 The benefits of haploidentical donors using PTCy-modified HSCT has 
been shown to confer several benefits over HLA-matched donors. These 
donors are readily available, highly motivated to donate in order to help cure a 
family member, and are more often available post-transplant. In the case of 
Croatia, though we have a source of potentially HLA-matched stem cells in our 
umbilical cord blood bank (6), a haploidentical HSCT is cheaper to source and 
perform. 
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  Conclusions from several studies at Johns Hopkins of the success of 
P have allowed them to achieve similar outcomes as matched sibling HSTCy CT 
and allowed them to forgo MUD searches except for the 5% of cases where the 
patient has no haploidentical options.  
 Our data indicate that, while the sample size was small and the protocols 
employed new to UHC Zagreb, results of graft rejection and GVHD were 
acceptable in comparison to HLA-matched patients as well as consistent with 
other studies of PTCy around the world.  
 This study is the first set of data of patients receiving haploidentical 
HSCT in Croatia and the promising findings should point to continuing progress 
in the standing of UHC Zagreb and its hematologist-oncologists as leaders in 
the region for treatment of hematologic malignancies.  
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